162 related articles for article (PubMed ID: 19633973)
1. Bevacizumab versus ranibizumab in the treatment of exudative age-related macular degeneration.
Gamulescu MA; Radeck V; Lustinger B; Fink B; Helbig H
Int Ophthalmol; 2010 Jun; 30(3):261-6. PubMed ID: 19633973
[TBL] [Abstract][Full Text] [Related]
2. Comparative study of intravitreal bevacizumab (Avastin) versus ranibizumab (Lucentis) in the treatment of neovascular age-related macular degeneration.
Landa G; Amde W; Doshi V; Ali A; McGevna L; Gentile RC; Muldoon TO; Walsh JB; Rosen RB
Ophthalmologica; 2009; 223(6):370-5. PubMed ID: 19590252
[TBL] [Abstract][Full Text] [Related]
3. [Effectivity and safety of bevacizumab intravitreal injections for exudative age-related macular degeneration treatment--6 months observations].
Małgorzata F
Klin Oczna; 2010; 112(7-9):213-6. PubMed ID: 21121123
[TBL] [Abstract][Full Text] [Related]
4. Intravitreal ranibizumab and bevacizumab for the treatment of nonsubfoveal choroidal neovascularization in age-related macular degeneration.
Roller AB; Amaro MH
Arq Bras Oftalmol; 2009; 72(5):677-81. PubMed ID: 20027409
[TBL] [Abstract][Full Text] [Related]
5. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration.
Goff MJ; Johnson RN; McDonald HR; Ai E; Jumper JM; Fu A
Retina; 2007; 27(4):432-8. PubMed ID: 17420694
[TBL] [Abstract][Full Text] [Related]
6. Bevacizumab versus ranibizumab in the treatment of exudative age-related macular degeneration: a retrospective study of 58 patients.
De Bats F; Grange JD; Cornut PL; Feldman A; Burillon C; Denis P; Kodjikian L
J Fr Ophtalmol; 2012 Nov; 35(9):661-6. PubMed ID: 23040443
[TBL] [Abstract][Full Text] [Related]
7. Long-term follow-up after multiple intravitreal bevacizumab injections for exudative age-related macular degeneration.
Tao Y; Libondi T; Jonas JB
J Ocul Pharmacol Ther; 2010 Feb; 26(1):79-83. PubMed ID: 20148662
[TBL] [Abstract][Full Text] [Related]
8. Duration of action of intravitreal ranibizumab and bevacizumab in exudative AMD eyes based on macular volume measurements.
Shah AR; Del Priore LV
Br J Ophthalmol; 2009 Aug; 93(8):1027-32. PubMed ID: 19429594
[TBL] [Abstract][Full Text] [Related]
9. Changing from bevacizumab to ranibizumab in age-related macular degeneration. Is it safe?
Karagiannis DA; Ladas ID; Parikakis E; Georgalas I; Kotsolis A; Amariotakis G; Soumplis V; Mitropoulos P
Clin Interv Aging; 2009; 4():457-61. PubMed ID: 20054410
[TBL] [Abstract][Full Text] [Related]
10. Intravitreal bevacizumab for exudative age-related macular degeneration in clinical practice.
Jonas JB; Tao Y; Schlichtenbrede FC
J Ocul Pharmacol Ther; 2011 Oct; 27(5):467-70. PubMed ID: 21682590
[TBL] [Abstract][Full Text] [Related]
11. [Retinal angiomatous proliferation with associated pigment epithelium detachment: anti-VEGF therapy].
Lommatzsch A; Heimes B; Gutfleisch M; Spital G; Dietzel M; Pauleikhoff D
Ophthalmologe; 2011 Mar; 108(3):244-51. PubMed ID: 20571805
[TBL] [Abstract][Full Text] [Related]
12. Effects of vitreomacular adhesion on anti-vascular endothelial growth factor treatment for exudative age-related macular degeneration.
Lee SJ; Koh HJ
Ophthalmology; 2011 Jan; 118(1):101-10. PubMed ID: 20678805
[TBL] [Abstract][Full Text] [Related]
13. Intravitreal bevacizumab combined with intravitreal triamcinolone for therapy-resistant exudative age-related macular degeneration.
Tao Y; Jonas JB
J Ocul Pharmacol Ther; 2010 Apr; 26(2):207-12. PubMed ID: 20415625
[TBL] [Abstract][Full Text] [Related]
14. Intravitreal ranibizumab and bevacizumab in combination with full-fluence verteporfin therapy and dexamethasone for exudative age-related macular degeneration.
Forte R; Bonavolontà P; Benayoun Y; Adenis JP; Robert PY
Ophthalmic Res; 2011; 45(3):129-34. PubMed ID: 20847575
[TBL] [Abstract][Full Text] [Related]
15. Intravitreal ranibizumab (Lucentis) in the treatment of retinal angiomatous proliferation (RAP).
Konstantinidis L; Mameletzi E; Mantel I; Pournaras JA; Zografos L; Ambresin A
Graefes Arch Clin Exp Ophthalmol; 2009 Sep; 247(9):1165-71. PubMed ID: 19404661
[TBL] [Abstract][Full Text] [Related]
16. The results of switching between 2 anti-VEGF drugs, bevacizumab and ranibizumab, in the treatment of neovascular age-related macular degeneration.
Aslankurt M; Aslan L; Aksoy A; Erden B; Cekiç O
Eur J Ophthalmol; 2013; 23(4):553-7. PubMed ID: 23516253
[TBL] [Abstract][Full Text] [Related]
17. Serous pigment epithelial detachment in age-related macular degeneration: comparison of different treatments.
Lommatzsch A; Heimes B; Gutfleisch M; Spital G; Zeimer M; Pauleikhoff D
Eye (Lond); 2009 Dec; 23(12):2163-8. PubMed ID: 19197318
[TBL] [Abstract][Full Text] [Related]
18. Retinal pigment epithelial tears after intravitreal bevacizumab injection for exudative age-related macular degeneration.
Garg S; Brod R; Kim D; Lane RG; Maguire J; Fischer D
Clin Exp Ophthalmol; 2008 Apr; 36(3):252-6. PubMed ID: 18412594
[TBL] [Abstract][Full Text] [Related]
19. Intravitreal bevacizumab vs verteporfin photodynamic therapy for neovascular age-related macular degeneration.
Bashshur ZF; Schakal A; Hamam RN; El Haibi CP; Jaafar RF; Noureddin BN
Arch Ophthalmol; 2007 Oct; 125(10):1357-61. PubMed ID: 17923543
[TBL] [Abstract][Full Text] [Related]
20. A systematic review on the effect of bevacizumab in exudative age-related macular degeneration.
Schouten JS; La Heij EC; Webers CA; Lundqvist IJ; Hendrikse F
Graefes Arch Clin Exp Ophthalmol; 2009 Jan; 247(1):1-11. PubMed ID: 18843500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
